BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience and Satiety Research

Executive Summary: BIIE 0246 is a highly potent antagonist against the neuropeptide Y Y2 receptor (Y2R), with an IC50 of 3.3 nM and Ki values between 8–15 nM in binding assays (APExBIO product data). It selectively blocks presynaptic Y2R-mediated inhibition, reversing the effects of NPY on neuronal and gastrointestinal models (Fan et al., 2024). BIIE 0246 is widely used to dissect the physiological role of Y2R in satiety, feeding behavior, and neurobehavioral assays. It provides robust pharmacological validation for Y2R as a therapeutic target in both neuroscience and cardiometabolic research. All findings cited herein are backed by peer-reviewed literature and stable product documentation.

Biological Rationale

The neuropeptide Y (NPY) system modulates central and peripheral processes such as feeding, anxiety, and cardiovascular function (Fan et al., 2024). The Y2 receptor (Y2R) is a G-protein-coupled receptor (GPCR) expressed broadly in the brain and peripheral tissues. Y2R mediates presynaptic inhibition of neurotransmitter release, notably in regions regulating satiety and stress. Elevated NPY and Y2R signaling are implicated in cardiac arrhythmias, metabolic syndrome, and anxiety disorders. Targeted antagonists like BIIE 0246 enable mechanistic dissection of these pathways. The rational inhibition of Y2R is essential for mapping the adipose-neural axis and its effects on cardiac excitability and post-prandial satiety (Fan et al., 2024).

Mechanism of Action of BIIE 0246

BIIE 0246 is a small molecule antagonist with high selectivity for Y2R (IC50: 3.3 nM; Ki: 8–15 nM for PYY3-36 binding) (APExBIO). It competitively blocks Y2R, inhibiting NPY- and PYY3-36-induced presynaptic inhibition. In rat hippocampal slices, BIIE 0246 suppresses NPY-mediated reduction of primary afterdischarge activity and population excitatory postsynaptic potentials. In gastrointestinal models, it abrogates PYY3-36-induced contraction in rat colon. The compound is also anxiolytic in behavioral assays, such as the elevated plus-maze. BIIE 0246 has no significant affinity for other NPY receptor subtypes at relevant concentrations (Estragolecas, 2023), ensuring target specificity.

Evidence & Benchmarks

• BIIE 0246 inhibits radiolabeled PYY3-36 binding to Y2R with Ki values of 8–15 nM at 22°C, pH 7.4 (APExBIO).
• Blocks NPY-induced inhibition of afterdischarge activity in rat hippocampal slices at 1–10 μM (Bath application, 35°C) (Gens Bio, 2023).
• Completely suppresses PYY3-36-induced contraction in isolated rat colon segments at 0.1–1 μM (Organ bath, 37°C) (Fan et al., 2024).
• Attenuates PYY(3-36)-induced reduction in food intake in rodent models when administered at 0.3–1 mg/kg, i.p. (GPCR.com, 2022).
• Produces anxiolytic-like effects in the elevated plus-maze at 0.5–2 mg/kg, i.p., without sedative side-effects (Estragolecas, 2023).
• BIIE 0246 shows no significant off-target effects in Y1R- or Y5R-dependent models at up to 10 μM (MSHRIF, 2024).

Applications, Limits & Misconceptions

BIIE 0246 is used to validate Y2R involvement in neural, metabolic, and cardiovascular models. It is indispensable for mapping the adipose-neural axis, as demonstrated in recent stem cell-based arrhythmia models (Fan et al., 2024). The compound is also a reference standard in feeding behavior and satiety studies, where it blocks PYY3-36 and NPY effects on food intake. In anxiety research, BIIE 0246's anxiolytic-like effects have clarified the role of Y2R in stress response without confounding sedation.

This article extends the analysis provided in "BIIE 0246: Selective Y2 Antagonism Illuminates Adipose-Neural Mechanisms" by integrating recent evidence from cardiac arrhythmia models and updating quantitative benchmarks. For a focused discussion on translational strategy and workflow pain points, see "BIIE 0246 (SKU B6836): Resolving Pain Points in NPY Y2R Research", whereas the present article emphasizes cross-domain applications and current parameter recommendations.

Common Pitfalls or Misconceptions

• BIIE 0246 does not block Y1R or Y5R at experimental concentrations up to 10 μM; off-target effects are minimal (MSHRIF, 2024).
• It is not intended for clinical or diagnostic use; all data are for research purposes only (APExBIO).
• Long-term storage of BIIE 0246 solutions (in DMSO or ethanol) is not recommended due to potential degradation (APExBIO).
• BIIE 0246's anxiolytic effect is not due to general CNS depression or sedation (Estragolecas, 2023).
• It cannot be used to infer Y2R involvement in species or tissues where receptor homology is unverified.

Workflow Integration & Parameters

BIIE 0246 is supplied as a white solid (C49H57N11O6, MW 896.06) by APExBIO. It dissolves to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol. For in vitro studies, stock solutions should be prepared fresh and stored at 4°C. For in vivo use, recommended doses range from 0.3–2 mg/kg i.p., with careful attention to solvent compatibility and animal welfare protocols. Y2R antagonism should be validated by loss-of-function assays and, where possible, receptor binding studies. Use appropriate negative controls and ensure that assay conditions (temperature, buffer, pH) match benchmarked protocols. For additional workflow scenarios and troubleshooting, refer to this guide.

Conclusion & Outlook

BIIE 0246 is a gold-standard tool for dissecting neuropeptide Y Y2 receptor function in neural, metabolic, and cardiovascular research. Its selectivity and potency enable rigorous mapping of the adipose-neural axis, feeding circuitry, and anxiety pathways. As new disease models highlight the role of NPY/Y2R signaling in arrhythmogenesis and metabolic syndrome, BIIE 0246 from APExBIO remains central to both basic and translational research. Future studies may extend its utility to novel disease contexts, provided rigorous species and tissue validation is performed.

For detailed product specifications, visit the official BIIE 0246 page (SKU B6836).